2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders

A method of treating panic disorder or anxiety disorder in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of the formula:

• ##STR26## R.sup.1 is H, C.sub.1 -C.sub.4 alkyl, cyclo-C.sub.3 -C.sub.7 -alkyl, ##STR27## NR.sup.4 R.sup.5, C.sub.1 -C.sub.4 -alkoxy, thio-C.sub.1 -C.sub.4 alkoxy, OH, or SH;
• R.sup.2 is H;
• C.sub.1 -C.sub.4 alkyl;
• mono- or disubstituted or unsubstituted phenyl, where the substitutent(s) is/are independently selected from the group consisting of halo, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, carboxyl, carboxy-C.sub.1 -C.sub.4 alkyl, nitro, --CF.sub.3, ##STR28## and hydroxy;
• 2-, 3- or 4-pyridyl;
• or --(CH.sub.2).sub.m COOR.sup.6 ;
• ##STR29## R.sup.4 and R.sup.5 are independently H, C.sub.1 -C.sub.4 alkyl, or cyclo-C.sub.3 -C.sub.7 alkyl or are connected to form a hetero ring of the structure --N(CH.sub.2).sub.k, wherein k is 2 to 6;
• R.sup.6 is H, C.sub.1 -C.sub.4 -alkyl, cyclo-C.sub.3 -C.sub.7 -alkyl, unsubstituted or mono- or disubstituted phenyl, wherein the substituent(s) is/are independently selected from the group consisting of halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, nitro, and CF.sub.3, or unsubstituted or mono- or disubstituted phenyl-C.sub.1 -C.sub.4 -alkyl, wherein the substituent(s) is/are selected from the group consisting of halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 -alkoxy, nitro, and CF.sub.3 ;
• R.sup.7 is .alpha.- or .beta.-naphthyl, unsubstituted or mono- or disubstituted phenyl, wherein the substituent(s) is/are independently selected from the group consisting of halo, --NO.sub.2, --OH, --NR.sup.4 R.sup.5, C.sub.1 -C.sub.4 alkyl, cyano, phenyl, trifluoromethyl, acetylamino, acetyloxy, C.sub.1 -C.sub.4 alkylthio, SCF.sub.3, C.dbd.CH, CH.sub.2 SCF.sub.3, OCHF.sub.2, S-phenyl, and C.sub.1 -C.sub.4 -alkoxy. ##STR30## R.sup.8 is H, C.sub.1 -C.sub.4 -alkyl, cyclo-C.sub.3 -C.sub.7 -alkyl, --(CH.sub.2).sub.n -cyclo-C.sub.3 -C.sub.7 -alkyl, ##STR31## p1 R.sup.9 is OH, OR.sup.11 or NR.sup.4 R.sup.5 ;
• R.sup.10 is H, --OH, or --CH.sub.3 ;
• R.sup.11 and R.sup.12 are independently C.sub.1 -C.sub.4 -alkyl or cyclo-C.sub.3 -C.sub.7 -alkyl;
• R.sup.13 is ##STR32## R.sup.14 is C.sub.1 -C.sub.4 -alkyl or phenyl-C.sub.1 -C.sub.4 -alkyl;
• R.sup.18 is H, C.sub.1 -C.sub.4 -alkyl, formyl, acetyl, propionyl or butyryl;
• m is 1 to 4;
• n is 0 to 4;
• q is 0 to 4;
• r is 1 to 2;
• X.sup.1 is H, --NO.sub.2, CF.sub.3 CN, OH, C.sub.1 -C.sub.4 -alkyl, halo, C.sub.1 -C.sub.4 -alkylthio, C.sub.1 -C.sub.4 -alkoxy, --(CH.sub.2).sub.n COOR.sup.6, --NR.sup.4 R.sup.5, or ##STR33## X.sup.2 and X.sup.3 are independently H, --OH, --NO.sub.2, halo C.sub.1 -C.sub.4 -alkylthio, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy or ##STR34## X.sup.4 is S, O, CH.sub.2, or NR.sup.8 ;
• X.sup.6 is O or HH;
• X.sup.8 is H or C.sub.1 -C.sub.4 -alkyl;
• X.sup.9 and X.sup.9.sub.a are independently NR.sup.18 or O;
• W is CR.sup.1, N or NH;
• Y is N, S, or O;
• Z is C--H or absent;
• and
• --is a saturated (single) or unsaturated (double) bond;
• or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.